These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 22738665)
1. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. Pai HH; Keyes M; Morris WJ; Christie J Brachytherapy; 2013; 12(2):126-33. PubMed ID: 22738665 [TBL] [Abstract][Full Text] [Related]
2. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis. Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533 [TBL] [Abstract][Full Text] [Related]
3. Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients. Keyes M; Spadinger I; Liu M; Pickles T; Pai H; Hayden A; Moravan V; Halperin R; McKenzie M; Kwan W; Agranovic A; Lapointe V; Morris WJ Brachytherapy; 2012; 11(3):199-208. PubMed ID: 21763213 [TBL] [Abstract][Full Text] [Related]
4. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Peters CA; Cesaretti JA; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):424-9. PubMed ID: 16887295 [TBL] [Abstract][Full Text] [Related]
5. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer. Yoshida K; Yamazaki H; Nakamara S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y Anticancer Res; 2014 Apr; 34(4):2015-8. PubMed ID: 24692740 [TBL] [Abstract][Full Text] [Related]
6. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer. Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495 [TBL] [Abstract][Full Text] [Related]
7. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881 [TBL] [Abstract][Full Text] [Related]
8. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402 [TBL] [Abstract][Full Text] [Related]
9. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939 [TBL] [Abstract][Full Text] [Related]
10. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
11. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma. Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084 [TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182 [TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838 [TBL] [Abstract][Full Text] [Related]
19. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy. Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108 [TBL] [Abstract][Full Text] [Related]
20. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]